Analysts didn't flinch... here's why
| *This email contains promotional content | Hey Folks, Jeff Bishop here, | The market inched up today, with traders weighing the prospect of a ceasefire deal with Iran. | We haven't been in the kind of environment where you'd expect small stocks to hold up well. | And yet, one I've been tracking has done exactly that. | After investors "sold the news" earlier this month following a Phase 2 data release, this stock has been steadily consolidating since March 9. | That's the kind of behavior I pay very close attention to. In small-cap biotech especially, these "sell the news" reactions can overshoot reality… | And when they do, the reset phase often comes before the next move higher. | What makes this one particularly interesting is that the Phase 2 data itself was positive — showing a 73% clinical clearance rate in the highest-dose cohort. | But the market didn't treat it that way. | Instead, the stock got hit hard in the days that followed, dropping roughly 65% from early March highs. | At the same time, analysts following the stock didn't back off. | In fact, one of the lead firms reaffirmed its "BUY" rating and $27 price target after the data drop. | So the stock drops, but the people paid to analyze the data in detail… stay bullish. | That kind of disconnect is where great "tactical trade" opportunities can show up. | And right now, the chart is starting to reflect that shift. Selling pressure appears to have dried up and volume has stayed elevated. | At 11:30 AM this morning, there's a scheduled webcast featuring the principal investigator behind the Phase 2 study — someone who can actually walk the market through what the data really means clinically. | I've broken down exactly what I'm seeing, why this setup stands out right now, and what could come next… | 👉 View Today's Tactical Trade Idea 👈 | This is one you'll want on your radar before the bell. | Especially with a catalyst hitting in a few hours. | To Your Success, | | P.S. -⚡Daily Action in Market Masters Trading Room Starting at 9am ET | (ALL are welcome) | | | DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC ("SV"). Full disclaimer: https://bullseyealerts.com/disclaimer/. | NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security. | *PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received thirty five thousand dollars (cash) from Medicus Pharma, Ltd (via Lifewater Media) for a one day marketing program starting on March 26, 2026 for marketing efforts to increase public awareness of the company mentioned on this page HERE. Please scroll to the bottom for full disclosure details including historical records (if applicable). As SV has received compensation from companies, these parties have financial interests in the securities referenced. SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice. | RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions. |
|
|
|
| | | | | Update your email preferences or unsubscribe here © 2026 Bullseye Trades 62 Calef Hwy. #233
Lee, NH 03861, United States | | Terms of Service | |
|
|
|
|
|
Tidak ada komentar:
Posting Komentar